Clinical Data, DHZ study value of genetic markers

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Ironwood stock offering aims for $80M [February 10, 2012]

Clinical Data Inc.’s PGxHealth division, which develops the Familion line of genetic tests, has formed a research collaboration with Deutsches Herzzentrum (DHZ) of Munich, Germany. The collaboration is intended to study the value of genetic markers, particularly in relation to clopidogrel, the anti-platelet medicine typically known as Plavix.

Researchers plan to study people taking clopidogrel with regards to genetic response to the drug and genetic predictors of future heart attack events. Currently, research has shown polymorphism of certain genes has affected clopidogrel response levels. Study results are expected next year.

Clinical Data (Nasdaq: CLDA) is developing early- and late-stage targeted therapeutics and genetic and pharmacogenomic tests that detect diseases and help predict drug safety, tolerability and effectiveness.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.